Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $26 to $25.